Cargando…

High levels of HB-EGF and interleukin-18 are associated with a high risk of in-stent restenosis

OBJECTIVE: To explore the clinical significance of heparin-binding epidermal growth factor-like growth factor (HB-EGF), interleukin-18 (IL-18), and interleukin-10 (IL-10) in restenosis after percutaneous coronary intervention (PCI). METHODS: A total of 198 patients with acute coronary syndrome under...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Hua, Liu, Wenwei, Liu, Yongshen, Cao, Fengsheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Kare Publishing 2016
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5336941/ https://www.ncbi.nlm.nih.gov/pubmed/25868040 http://dx.doi.org/10.5152/akd.2015.5798

Ejemplares similares

Visit-to-visit HbA(1c) variability is associated with in-stent restenosis in patients with type 2 diabetes after percutaneous coronary intervention
por: Yang, Chen Die, et al.
Publicado: (2020)

Associations of myeloperoxidase, interleukin-17A and heparin-binding EGF-like growth factor levels with in-stent restenosis after percutaneous coronary intervention: a single-centre case–control study in China
por: Jiang, Hua, et al.
Publicado: (2020)

Middle and Distal Common Carotid Artery Stenting: Long-Term Patency Rates and Risk Factors for In-Stent Restenosis
por: Vértes, Miklós, et al.
Publicado: (2020)

An increase of interleukin-33 serum levels after coronary stent implantation is associated with coronary in-stent restenosis
por: Demyanets, Svitlana, et al.
Publicado: (2014)

In-stent restenosis of drug-eluting stents in patients with diabetes mellitus: Clinical presentation, angiographic features, and outcomes
por: Paramasivam, Ganesh, et al.
Publicado: (2020)

Reducing In-Stent Restenosis: Therapeutic Manipulation of miRNA in Vascular Remodeling and Inflammation
por: McDonald, Robert A., et al.
Publicado: (2015)

Triglyceride-glucose index is associated with in-stent restenosis in patients with acute coronary syndrome after percutaneous coronary intervention with drug-eluting stents
por: Zhu, Yong, et al.
Publicado: (2021)

Value of M2BP in predicting in‐stent restenosis in patients after coronary drug‐eluting stent implantation
por: Yang, Le, et al.
Publicado: (2022)

Identification of the Cancer Cell Proliferation and Survival Functions of proHB-EGF by Using an Anti-HB-EGF Antibody
por: Sato, Shuji, et al.
Publicado: (2013)

Hypersensitivity and in-stent restenosis in coronary stent materials
por: Hu, Wansong, et al.
Publicado: (2022)

Correlation between high perfusion syndrome and stent restenosis after stent implantation
por: Li, Yingyi, et al.
Publicado: (2016)

A Potent Anti-HB-EGF Monoclonal Antibody Inhibits Cancer Cell Proliferation and Multiple Angiogenic Activities of HB-EGF
por: Sato, Shuji, et al.
Publicado: (2012)

Drug-eluting stent in-stent restenosis and re-restenosis: A hard time story
por: Dinesch, Violeta, et al.
Publicado: (2017)

Glycosylated hemoglobin (HbA1c) levels and clinical outcomes in diabetic patients following coronary artery stenting
por: Kassaian, Seyed Ebrahim, et al.
Publicado: (2012)

Clinical implication of quantitative flow ratio to predict clinical events after drug‐coated balloon angioplasty in patients with in‐stent restenosis
por: Tang, Jiani, et al.
Publicado: (2021)

Viabahn for femoropopliteal in-stent restenosis
por: Al Shammeri, Owayed, et al.
Publicado: (2012)

Current Management of In-Stent Restenosis
por: Her, Ae-Young, et al.
Publicado: (2018)

Calcified in-stent restenosis in a venous stent
por: Schmidt, Jens-Ove, et al.
Publicado: (2015)

Therapeutic Strategy for In-Stent Restenosis Based on the Restenosis Pattern After Drug-Eluting Stent Implantation
por: Kim, Ki-Hun, et al.
Publicado: (2009)

Response to drug-eluting stent in-stent restenosis and re-restenosis: A hard time story
Publicado: (2017)

Correlation of IL-1 and HB-EGF with endometrial receptivity
por: Wang, Hui, et al.
Publicado: (2018)

Associations of human leukocyte antigen and interleukin-18 gene polymorphisms with viral load in patients with hepatitis B infection
por: Jiang, Hua, et al.
Publicado: (2018)

In-stent restenosis and longitudinal stent deformation: a case report
por: Si, Daoyuan, et al.
Publicado: (2020)

Characterization of a Novel Anti-Human HB-EGF Monoclonal Antibody Applicable for Paraffin-Embedded Tissues and Diagnosis of HB-EGF-Related Cancers
por: Iwamoto, Ryo, et al.
Publicado: (2016)

APF, HB-EGF, and EGF biomarkers in patients with ulcerative vs. non-ulcerative interstitial cystitis
por: Zhang, Chen-Ou, et al.
Publicado: (2005)

Overlap stenting for in-stent restenosis after carotid artery stenting
por: Nishihori, Masahiro, et al.
Publicado: (2016)

Compositional and functional properties of high-density lipoproteins in relation to coronary in-stent restenosis
por: Ganjali, Shiva, et al.
Publicado: (2021)

In Stent Restenosis Predictors after Carotid Artery Stenting
por: Cosottini, Mirco, et al.
Publicado: (2010)

Intracoronary brachytherapy for in-stent restenosis of drug-eluting stents
por: Ohri, Nisha, et al.
Publicado: (2015)

Switching types of drug-eluting stents does not prevent repeated in-stent restenosis in patients with coronary drug-eluting stent restenosis
por: Nojima, Yuhei, et al.
Publicado: (2014)

Treatment of Femoropopliteal Artery In-stent Restenosis
por: Kim, Wonho, et al.
Publicado: (2018)

Aortoiliac reconstruction in the setting of in-stent restenosis
por: Natraj Setty, H. S., et al.
Publicado: (2017)

The number of stents was an independent risk of stent restenosis in patients undergoing percutaneous coronary intervention
por: Tang, Long, et al.
Publicado: (2019)

Genetic risk model for in-stent restenosis of second-and third-generation drug-eluting stents
por: Liu, Yen-Wen, et al.
Publicado: (2021)

Remnant lipoproteins play an important role of in-stent restenosis in type 2 diabetes undergoing percutaneous coronary intervention: a single-centre observational cohort study
por: Qin, Zheng, et al.
Publicado: (2019)

Inverse Relationship between Serum VEGF Levels and Late In-Stent Restenosis of Drug-Eluting Stents
por: Yin, Jiasheng, et al.
Publicado: (2017)

Drug-Eluting Stent as an Option for Intractable In-Stent Coronary Restenosis
por: Hachinohe, Daisuke, et al.
Publicado: (2011)

Intravascular Imaging for Guiding In‐Stent Restenosis and Stent Thrombosis Therapy
por: Erdogan, Emrah, et al.
Publicado: (2022)

The long-term prognostic significance of high-sensitive C-reactive protein to in-stent restenosis
por: Zhu, Xinyi, et al.
Publicado: (2018)

Data on the expression and role of TREM-1 in the development of in-stent restenosis
por: Wang, Fang, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_376pt53ms3vq3kbb32v7v3gjru